Filing summary
Issuer and period: The supplied filing is Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation), not SELLAS Life Sciences Group, Inc. It is an unaudited Form 10-Q for the quarter ended September 30, 2011, filed November 14, 2011. The company described itself as a development-stage biotechnology business focused on oncology, including NeuVax (E75). It reported no revenue since inception.
Financial performance and liquidity
| Metric | Q3 2011 / September 30, 2011 | Comparable period / prior balance date |
|---|---|---|
| Revenue | None | None reported since inception |
| Research and development expense | $3.002 million for Q3; $7.835 million for nine months | Q3 2010: $1.936 million; nine months 2010: $6.126 million |
| General and administrative expense | $2.074 million for Q3; $7.142 million for nine months | Q3 2010: $1.783 million; nine months 2010: $6.803 million |
| Operating loss | $5.076 million for Q3; $14.977 million for nine months | Q3 2010: $3.719 million; nine months 2010: $12.929 million |
| Net loss / diluted loss per share | $5.475 million / $0.13 for Q3; $13.074 million / $0.39 for nine months | Q3 2010: $4.135 million / $0.23; nine months 2010: $10.162 million / $0.57 |
| Cash and cash equivalents | $15.693 million | $6.891 million at December 31, 2010; $2.836 million at September 30, 2010 |
| Cash flows, nine months | Operating: $(10.499) million; investing: $0.115 million provided; financing: $19.186 million provided | 2010: operating $(8.388) million; investing $(6.055) million; financing $11.595 million provided |
| Total assets / total liabilities | $30.329 million / $25.620 million | December 31, 2010: $7.476 million / $5.046 million |
Margins are not meaningful because the company had no revenue. At September 30, 2011, current liabilities were $21.461 million, including $15.226 million of warrants potentially settleable in cash, $500,000 of convertible notes, and $1.632 million of current contingent acquisition consideration. The company also reported $4.145 million of noncurrent contingent purchase consideration and $14,000 of noncurrent capital lease obligations.
Changes versus prior periods
- Q3 net loss increased 32% year over year, and nine-month net loss increased 29%. Management attributed higher operating losses mainly to increased NeuVax-related research and development and higher professional and other administrative costs.
- Nine-month operating cash use increased by approximately $2.111 million year over year. Financing cash inflows rose, primarily from 2011 stock offerings and $500,000 of convertible notes.
- The April acquisition of Apthera added NeuVax-related assets, including $12.864 million of in-process research and development and $845,000 of goodwill. Consideration included approximately 5.0 million shares and contingent payments of up to $32 million; the recorded fair value of contingent consideration was $5.777 million at quarter-end.
- Common shares outstanding increased from 18.373 million at December 31, 2010 to 42.985 million at September 30, 2011. The 2011 financings included substantial warrant issuance; offering-related price adjustments reduced certain warrant exercise prices to $0.65.
Outlook, risks and unusual items
- Management said cash was expected to fund operations for the next 12 months, but anticipated continued significant losses, rising development costs, and dependence on future financing, grants, or collaborations. It cautioned that additional funding may not be available on acceptable terms or at all.
- The company expected to commence the NeuVax Phase 3 trial by the first half of 2012. The MD Anderson/Henry M. Jackson Foundation license included a $200,000 milestone upon Phase 3 commencement, annual maintenance fees, and potential royalties.
- Galena contributed substantially all RNAi assets and $1.5 million to subsidiary RXi and planned an RXi spin-off. The proposed investor financing included $9.5 million of preferred stock and up to $1.5 million of bridge lending; completion was conditional, and there was no assurance the financing or spin-off would close. Galena guaranteed the RXi bridge notes and pledged its RXi shares as security.
- On October 28, 2011, Hudson Bay demanded $1.372 million to repurchase a warrant, alleging the September name-change merger triggered a contractual provision. Galena disputed the claim and said the outcome could not be predicted.
- Management identified material weaknesses in controls over valuation of certain options and warrants after an erroneous volatility input led to a restatement of the June 2011 interim financial statements. Management said it believed the calculation weakness had been remedied, but disclosure controls for this area were not effective at September 30.
- Fair-value changes materially affected reported results: the company recorded a $900,000 loss on an exchange of equity instruments and noncash warrant and contingent-consideration valuation adjustments. The warrant liability rose to $15.226 million from $3.138 million at year-end.
Investor verification points
- Confirm issuer identity: the supplied 10-Q is for Galena Biopharma, not SELLAS Life Sciences Group.
- Verify the status and terms of the RXi spin-off, investor financing, bridge-loan guarantee, and any resulting effect on Galena’s cash and obligations.
- Review the warrant liability valuation, potential cash-settlement provisions, and the financial impact of the control weakness and June restatement.
- Track NeuVax Phase 3 timing, related license milestones and fees, and the contingent Apthera acquisition payments.
- Assess whether cash runway remains consistent with management’s 12-month estimate given continuing operating cash use and the company’s stated need for future funding.